These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 2131793

  • 1. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
    Salmon SE, Tesh D, Crowley J, Saeed S, Finley P, Milder MS, Hutchins LF, Coltman CA, Bonnet JD, Cheson B.
    J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
    [Abstract] [Full Text] [Related]

  • 2. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
    Durie BG, Dixon DO, Carter S, Stephens R, Rivkin S, Bonnet J, Salmon SE, Dabich L, Files JC, Costanzi JJ.
    J Clin Oncol; 1986 Aug; 4(8):1227-37. PubMed ID: 3525768
    [Abstract] [Full Text] [Related]

  • 3. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B.
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [Abstract] [Full Text] [Related]

  • 4. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
    Boccadoro M, Marmont F, Tribalto M, Avvisati G, Andriani A, Barbui T, Cantonetti M, Carotenuto M, Comotti B, Dammacco F.
    J Clin Oncol; 1991 Mar; 9(3):444-8. PubMed ID: 1999714
    [Abstract] [Full Text] [Related]

  • 5. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
    Bladé J, San Miguel JF, Alcalá A, Maldonado J, Sanz MA, García-Conde J, Moro MJ, Alonso C, Besalduch J, Zubizarreta A.
    J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma.
    Nagura E, Ichikawa A, Kamiya O, Kato R, Utsumi M, Tanaka M, Takeyama H, Shimizu K, Kobayashi M, Naito K, Nishiwaki H, Mizuno H, Hirabayashi N, Nitta M, Kato Y, Shibata T, Hotta T, Kawashima K, Saito H.
    Cancer Chemother Pharmacol; 1997 Jun; 39(4):279-85. PubMed ID: 9025767
    [Abstract] [Full Text] [Related]

  • 12. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
    Cohen AM, Meytes D, Many A, Brenner B, Aghai E, Shaklai M, Kaufman S, Shtalrid M, Attias D, Manor Y.
    Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
    [Abstract] [Full Text] [Related]

  • 13. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
    Bonnet J, Alexanian R, Salmon S, Bottomley R, Amare M, Haut A, Dixon D.
    Cancer Treat Rep; 1982 Jun; 66(6):1267-71. PubMed ID: 7044534
    [Abstract] [Full Text] [Related]

  • 14. Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment.
    Cohen HJ, Bartolucci AA, Forman WB, Silberman HR.
    J Clin Oncol; 1986 Jun; 4(6):888-99. PubMed ID: 3519879
    [Abstract] [Full Text] [Related]

  • 15. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM, Leong T, Lenhard RE, Greipp PR, Kay NE, Van Ness B, Keimowitz RM, Kyle RA.
    Cancer; 1999 Sep 15; 86(6):957-68. PubMed ID: 10491521
    [Abstract] [Full Text] [Related]

  • 16. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
    Zervas K, Pouli A, Gregoraki B, Anagnostopoulos N, Dimopoulos MA, Bourantas K, Tzilianos M, Barbarousi D, Venetis E, Vyniou N, Maniatis A.
    Eur J Haematol; 2001 Jan 15; 66(1):18-23. PubMed ID: 11168503
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].
    Wutke K, Anger G.
    Z Gesamte Inn Med; 1983 Dec 01; 38(23):630-3. PubMed ID: 6689459
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
    Ludwig H, Cohen AM, Huber H, Nachbaur D, Jungi WF, Senn H, Günczler P, Schüller J, Eckhardt S, Seewann HL.
    Eur J Cancer; 1991 Dec 01; 27 Suppl 4():S40-5. PubMed ID: 1799476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.